—As more men are cured of prostate cancer, or are long-term survivors, the challenges of survivorship are in the spotlight. Improved screening practices, earlier detection, and better therapies have ...

A new study published in The New England Journal of Medicine showed that when compared to androgen deprivation therapy (ADT) ...

ADT plus apalutamide before and after surgery significantly improved metastasis-free survi ...

Two types of androgen deprivation therapy (ADT) had different effects on coronary atherosclerosis in a small randomized trial of men with prostate cancer. Significantly more coronary artery plaque ...

I f prostate cancer has spread to other areas of your body, your doctor may recommend androgen deprivation therapy (ADT), which halts the production of androgen hormones, especially testosterone.

The metastatic prostate cancer market is undergoing a major transition from conventional ADT toward combination-based, biomarker-driven, and precision-targeted treatment approaches. While AR pathway ...

A previous trial involving patients with metastatic prostate cancer that was resistant to androgen pathway modulation (formerly referred to as castration-resistant) showed that adding talazoparib ...

Perioperative treatment with apalutamide and androgen deprivation therapy (ADT) is beneficial for patients with high-risk ...

New data now show that perioperative systemic therapy with apalutamide can improve outcomes after radical prostatectomy.

Radical prostatectomy is potentially curative in patients with high-risk localized or locally advanced prostate cancer; however, relapse occurs within 5 years in up to 50% of patients. We ...

An analysis of four randomized controlled studies in patients with advanced prostate cancer who had received early vs. deferred ADT as primary therapy showed that early androgen suppression ...

JCO Precision Oncology Conversations podcasts feature discussions with leading authors of JCO Precision Oncology articles, hosted by Dr. Abdul Rafeh Naqash. Join our experts in engaging conversations ...